Constellation Brands STZ

Reference table

1. What it is

Constellation Brands (NYSE: STZ) is a Rochester, NY beverage company founded in 1945. After the 2025 divestiture of most of its wine & spirits portfolio, it is now overwhelmingly a US beer business built on the American rights to a set of Mexican import brands — Modelo Especial, Corona Extra/Familiar, Pacifico, Victoria, and the Modelo Chelada line. A residual, higher-end Wine & Spirits unit remains (The Prisoner, Robert Mondavi, Kim Crawford, Mi CAMPO Tequila, High West). Fiscal year ends the last day of February; the most recent reported quarter is Q1 FY2027 (ended 2026-05-31).

Revenue mix (FY2026, from filings):

• By product: Beer $8.32B (~91%) · Wine & Spirits $0.82B (~9%). The wine/spirits line collapsed year-over-year (from $1.67B in FY25) because of the divestitures — the story now is beer.
• By geography: United States $9.01B (~99%) · Non-US ~$0.13B. This is a domestic-demand business, but with a Mexican-import cost base — a geographic mismatch that is the crux of the tariff risk (§11).

The strategic reality: Constellation bet its future on premium Mexican beer in the US, and that bet drove a decade of share gains. The question now is whether that engine has matured just as its core consumer softens and trade policy turns against Mexican imports.

2. The expert thesis — (no coverage)

There is no expert coverage of STZ in the Synthos knowledge base: total_claims = 0, 0 net-bullish voices, 0 traceable claims. We will not manufacture conviction we do not have. Nothing in this note cites a claim_id, because none exist for this name.

That means the verdict below is fundamentals- and quant-driven: reported financials, live analyst estimates (FMP), management's own guidance (§9, half-weighted), the price-target consensus (as context only), and our own scenario model. Where the Street is bullish (25 Buy ratings, $169 median target), we treat that as one input, not our anchor — and we land more cautiously than the sell side because the top-line and trade-policy risks are, in our read, under-weighted at a Buy consensus.

3. Synthos scores & the Bull / Base / Bear cases

The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):

The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. Instead the cases bound the range, and the scores above summarize them. EPS below refers to comparable (adjusted) EPS, the metric management and the Street anchor on; FY26 comparable EPS was $11.82.

Synthos fair value = the base case, ~$160 (+16%), with the full $113–$200 span as the honest range. Our base sits below the Street's $169 median because we give more weight to the top-line decline and tariff overhang. Note the base case's +16% is real, but it is entirely a valuation re-rate off a cheap multiple — there is little-to-no earnings growth doing the work, which is exactly why the verdict is Watch, not Buy. This is a tracked call — the Forecaster Scorecard grades it once it matures.

4. Exponential Potential

Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). STZ is neither right now — it is a mature cash cow in mild decline:

• Forward growth: revenue is essentially flat-to-down (FY26 $9.14B, −10% YoY after divestitures; management guides FY27 organic net sales −1% to +1%). Comparable EPS CAGR FY27E→FY31E is only ~6.4% ($11.79 → ~$15.10 on consensus) — and a large share of that is share-count reduction from buybacks, not unit growth.
• Acceleration (the 2nd derivative) is negative. Beer depletions turned negative in Q1 FY27 (Modelo Especial ~−2%, Corona Extra >−5%), only partly offset by Pacifico/Victoria/Chelada. The decade-long premium-Mexican-beer share-gain story is decelerating.
• Room to run: at $23.5B market cap the company is not capacity-capped, but its addressable market — US premium beer — is mature and shrinking in volume terms industry-wide (younger cohorts drinking less; GLP-1 appetite-suppression is an emerging category headwind). Room to run is limited by demand, not by size.
• Reinvestment runway: the one genuine growth investment is the third Mexican brewery at Veracruz — real capacity, but it adds Mexican-sourced supply precisely as tariff risk on Mexican imports rises. Capex is guided down to ~$800M (from ~$1.2B), i.e. the build-out is winding, not accelerating.

Exponential Potential: Low (2/10). Own STZ, if at all, for value + a ~3% dividend + buyback-driven EPS, never for a multibagger. A small, accelerating beverage name would score far higher; STZ scores low precisely because it is large, single-category, and decelerating.

5. Financials (real numbers — FMP annual/quarterly)

• Revenue: FY26 $9.14B, −10.5% (FY25 $10.21B). Most of the decline is the wine/spirits divestiture, but even the beer engine is now growing only low-single-digits (Q1 FY27 beer net sales +2%). Multi-year context: revenue peaked near $10.2B (FY25) and has re-based lower.
• Quarterly trajectory: Q1 FY27 (2026-05-31) revenue $2.43B, −3% YoY; reported EPS $3.79, comparable EPS $3.43 (+7%). Beer operating margin held ~39%; wine/spirits remains a drag.
• Margins (TTM): gross 52.6%, EBITDA 35.1%, operating ~32%, net 20.1%. Beer is a genuinely high-margin franchise — the quality is in the margin, not the growth.
• Earnings: FY26 GAAP net income $1.69B, GAAP EPS $9.62 (recovered from an FY25 GAAP loss of −$0.45 driven by large non-cash wine/spirits impairments). Comparable FY26 EPS was $11.82. The gap between GAAP and comparable is almost entirely goodwill/intangible write-downs on the wine business — a real signal that past M&A destroyed value.
• Cash flow: FY26 operating CF $2.67B, capex −$0.88B, FCF ~$1.79B (FCF yield ~7.8%). Q1 FY27 FCF $485M (+9%). Cash generation is the strongest part of the story.
• Balance sheet: total debt $11.2B, net debt $11.1B, net-debt/EBITDA 3.28× TTM — management targets 3.0×. Elevated for a consumer staple; interest coverage ~8.5× is adequate but leverage limits flexibility and is a downside-risk driver.

6. Valuation — cheap, but cheap for reasons

STZ is statistically cheap: 13.1× trailing GAAP EPS, ~12× FY27E comparable EPS, 10.7× EV/EBITDA, 3.7× EV/sales, and a ~7.8% free-cash-flow yield with a ~3.0% dividend. On a PEG-style read the multiple is low even against modest growth. The bull case is simply: a durable, high-margin beer franchise should not trade at a market-discount multiple.

The bear rebuttal — and why we don't just call it a Buy — is that the cheapness is the market pricing three real problems: (1) revenue is declining, not growing; (2) ~100% of beer COGS is Mexican-sourced into a US tariff regime; (3) leverage is 3.3×. Cheap staples with shrinking volumes and a policy overhang can stay cheap or get cheaper (a value trap). Street targets (context): consensus/median ~$169–$174, high $197, low $139 — the sell side effectively assumes a re-rate and stabilization. Our base $160 credits the re-rate but not a growth inflection, so it lands below consensus. Not a value trap on our numbers, but not a table-pounding value buy either — a Watch.

7. Technicals (computed from EOD price history)

• Trend: down. $137 sits below the 50-DMA ($145) and 200-DMA ($146), with the 50 essentially on top of the 200 — no uptrend support. MACD −1.54 (negative).
• Location: −22% off the 52-week high ($176), only +7.7% off the 52-week low ($128) — nearer the lows than the highs. Max drawdown from peak −49.6% — this stock has roughly halved from its cycle high.
• Momentum: RSI(14) 41 — soft, below the 50 midline but not yet oversold (>30 clears the extreme-panic flag).
• Relative strength (the tell): STZ −17.4% 12-mo vs SPY +20.6% and QQQ +30.3%; −9% 3-mo vs SPY +14%. Persistent, broad underperformance of both the market and growth.
• Read: technicals do not confirm any bull thesis — this is a downtrending, underperforming name. For a value buyer that argues patience: there is no momentum reason to rush, and a base needs to form. This reinforces Watch over Buy.

8. Moat & competitive position

Constellation's moat is narrow but real: perpetual US brand rights to Modelo, Corona, and Pacifico, iconic import brands with genuine pricing power (Modelo Especial is the #1 US beer by dollar sales, and STZ was the #1 dollar-share gainer in Circana US tracked channels in Q1 FY27). High beer operating margins (~39%) and strong distributor relationships are durable. The limits of the moat: it is a single-category, single-geography-of-supply franchise; the US beer category is mature and volume-declining; and the core consumer skews to a Hispanic demographic whose spending has softened. The wine/spirits arm has negative competitive standing — hence the divestitures and impairments.

Peer set (market cap): Brown-Forman $12.2B (the closest pure alcohol comp), FEMSA $44.1B, Coca-Cola FEMSA $22.6B, Church & Dwight $23.4B, General Mills $20.1B, Tyson $21.0B, Bunge $20.7B, Dollar General $26.1B, Dollar Tree $23.8B. Within staples STZ has better margins than most food peers but worse growth and higher leverage than the beverage majors — the classic "high-quality asset, low-quality moment" profile.

9. Management, capital allocation & guidance

• Capital allocation: balanced and shareholder-friendly — FY26 returned ~$924M in buybacks + ~$716M in dividends, and $324M of buybacks YTD through June 2026, while holding the ~3.0× net-leverage target. The dividend (~$4.12/yr, ~3.0% yield, ~39% payout) looks well-covered by ~$1.8B FCF. Capex is being pared to ~$800M as the Veracruz brewery build progresses. This is textbook mature-cash-cow capital return.
• Insider activity: routine in the sampled window — RSU awards/vesting and a small officer sale (~4,400 shares at ~$143 by an EVP on 2026-05-13). No cluster of alarming discretionary selling, but also no conviction insider buying to signal a bottom.
• Management's own guidance (the earnings-call track, half-weighted — they talk their book). From the Q1 FY2027 earnings release (SEC 8-K, 2026-06-30), management's own stated FY27 outlook:

- Comparable EPS $11.20 – $11.90 (vs FY26 comparable $11.82) and reported EPS $11.50 – $12.20 (vs FY26 reported $9.61) — i.e. essentially flat comparable earnings.

- Enterprise organic net sales −1% to +1%; beer −1% to +1%; wine & spirits organic −1% to +1%. Explicitly guiding to no growth.

- Enterprise operating margin 32–33%; beer 37–38%.

- Operating cash flow $2.4–$2.5B, capex ~$800M, free cash flow $1.6–$1.7B.

- Reaffirmed the ~3.0× target net leverage and dividend ($1.03/qtr Class A).

This is a credible, self-consistent release (revenue, segment detail, explicit FY27 outlook) — and notably, management is guiding to flat sales and flat comparable EPS itself. That candor is a point in its favor, but it is also confirmation that the growth engine has stalled. Half-weighted, it supports our Base case, not the bull.

10. Catalysts & what to watch

• Next earnings: 2026-10-01 (Q2 FY27; Street EPS $3.61, revenue ~$2.55B). The key lines: beer depletion trend (is the Modelo/Corona decline stabilizing?) and any tariff cost commentary.
• US–Mexico trade policy: any change in tariffs on Mexican imports directly hits COGS on ~100% of beer volume — the single biggest external swing factor.
• Depletions vs shipments: shipments +1.8% but depletions −0.3% in Q1 FY27 — if depletions (true consumer pull) keep falling, shipments and margin follow.
• Leverage & buyback: progress toward 3.0× and the pace of repurchase (the main EPS lever in a flat-sales world).
• Category headwinds: GLP-1 / lower-alcohol-consumption trends among younger cohorts — a slow structural threat to volume.

Thesis tripwires (what would change the call): Upgrade to Buy if depletions turn positive for two quarters AND tariff risk clears, with the stock basing above its 200-DMA. Downgrade to Avoid if a tariff step-up compresses beer margin below ~35%, or depletions accelerate downward and leverage drifts above ~3.5×.

11. Key risks

• Mexican-import / tariff exposure (structural): ~100% of beer is brewed in Mexico and sold in the US. A US tariff on Mexican goods hits COGS directly and is a persistent overhang on both margin and sentiment.
• Volume decline in the core: beer depletions negative (Modelo −2%, Corona >−5% in Q1 FY27); a softening Hispanic consumer and a maturing US beer category threaten the volume base.
• Leverage (3.3× net-debt/EBITDA): limits flexibility; interest expense ~$350M/yr; a demand or margin stumble is amplified by the debt.
• Value-trap risk / de-rating: a cheap multiple can persist or compress if the top line keeps shrinking; the −50% drawdown and downtrend show the market is not yet convinced.
• Prior M&A destroyed value: the wine/spirits impairments and divestitures (FY25 GAAP loss) are a real capital-allocation black mark — evidence management overpaid before.
• Category disruption: GLP-1s and a secular drift toward lower alcohol consumption among younger consumers.
• No expert coverage: we have zero KB conviction to lean on — the call rests entirely on quant + fundamentals, which is itself a (lower-confidence) caveat.

12. Verdict, position sizing & monitoring

Watch. Constellation is a cheap (13× earnings, ~7.8% FCF yield, ~3% dividend), high-margin beer franchise — but it is shrinking, not growing: FY26 revenue −10%, beer depletions negative, management itself guiding FY27 to flat organic sales and flat comparable EPS, all while carrying 3.3× leverage and a Mexican-import/tariff overhang and trading in a clear downtrend (−17% 12-mo, −50% from its peak). The valuation gives a real ~+16% base-case re-rate, but that upside is purely multiple, not earnings — not enough, against these headwinds and a downtrending chart, to clear a Buy bar. There is no expert coverage to add conviction either way.

• Sizing: if owned as an income/value satellite, ~1–2% — not a core position while the trend and depletions are negative. New money can afford to wait for the tripwire (depletions turning + a technical base) rather than catch the falling knife.
• Monitoring: re-underwrite on the §10 tripwires; formal re-score each earnings print (next 2026-10-01). This verdict is logged as a tracked Synthos call as of 2026-07-03 at $137.47.
• Single biggest risk: US tariffs on Mexican imports plus softening core beer demand — both strike the ~91% beer engine at once.

Provenance & disclosures

• Traceability: 0 KB claims, breadth 0 — this name has no expert coverage in the Synthos knowledge base, and no claim_id is cited anywhere in this note. The verdict is explicitly fundamentals- and quant-driven. Fabricated conviction is structurally impossible (claim-ID reconciliation), and here we simply have none to reconcile.
• Data as-of: fundamentals 2026-05-31 (Q1 FY27) · estimates & prices 2026-07-02/03 · management guidance from the SEC 8-K earnings release dated 2026-06-30. Forward figures are analyst consensus (FMP) or management guidance, labeled as estimates/guidance.
• Management caveat: FY27 guidance is management's own book, half-weighted by design — and notably it guides to flat sales/EPS itself.
• Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
• Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").